No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Share Price Could Signal Some Risk
Nanjing King-Friend Biochemical Pharmaceutical Gets US FDA Nod for Type 2 Diabetes Injectable
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): The product Liraglutide injection has received the pharmaceutical registration approval from the USA FDA.
On April 3, Gelonghui announced that Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) recently received an approval letter from the USA Food and Drug Administration (referred to as "USA FDA") for liraglutide injection, 18mg/3mL (6mg/mL), (ANDA No.: 218115). Indications: as an adjunct to diet and exercise to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. To reduce the risk of major cardiovascular adverse events in adults with type 2 diabetes accompanied by cardiovascular disease.
Insiders Were the Biggest Winners as Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Market Cap Grew by CN¥1.1b Last Week
NKFPharma Gets Regulatory Nod for Muscle Relaxant Injection
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
